181 related articles for article (PubMed ID: 30096071)
1. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.
Colin de Verdiere N; Durier C; Samri A; Meiffredy V; Launay O; Matheron S; Mercier-Delarue S; Even S; Aboulker JP; Molina JM; Autran B; Simon F;
AIDS; 2018 Oct; 32(16):2291-2299. PubMed ID: 30096071
[TBL] [Abstract][Full Text] [Related]
2. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients.
Avelino-Silva VI; Miyaji KT; Hunt PW; Huang Y; Simoes M; Lima SB; Freire MS; Caiaffa-Filho HH; Hong MA; Costa DA; Dias JZ; Cerqueira NB; Nishiya AS; Sabino EC; Sartori AM; Kallas EG
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005219. PubMed ID: 27941965
[TBL] [Abstract][Full Text] [Related]
3. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients.
Avelino-Silva VI; Miyaji KT; Mathias A; Costa DA; de Carvalho Dias JZ; Lima SB; Simoes M; Freire MS; Caiaffa-Filho HH; Hong MA; Lopes MH; Sartori AM; Kallas EG
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):189-95. PubMed ID: 26361176
[TBL] [Abstract][Full Text] [Related]
4. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine.
Collaborative group for studies on yellow fever vaccines
Vaccine; 2019 Aug; 37(35):5129-5135. PubMed ID: 31171393
[TBL] [Abstract][Full Text] [Related]
5. Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule.
Veit O; Domingo C; Niedrig M; Staehelin C; Sonderegger B; Héquet D; Stoeckle M; Calmy A; Schiffer V; Bernasconi E; Flury D; Hatz C; Zwahlen M; Furrer H;
Clin Infect Dis; 2018 Mar; 66(7):1099-1108. PubMed ID: 29140432
[TBL] [Abstract][Full Text] [Related]
6. Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.
Kareko BW; Booty BL; Nix CD; Lyski ZL; Slifka MK; Amanna IJ; Messer WB
J Infect Dis; 2020 Jun; 221(12):2018-2025. PubMed ID: 31545367
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.
Sidibe M; Yactayo S; Kalle A; Sall AA; Sow S; Ndoutabe M; Perea W; Avokey F; Lewis RF; Veit O
Trans R Soc Trop Med Hyg; 2012 Jul; 106(7):437-44. PubMed ID: 22627101
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
Roukens AHE; van Halem K; de Visser AW; Visser LG
Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.
Pistone T; Verdière CH; Receveur MC; Ezzedine K; Lafon ME; Malvy D
Curr HIV Res; 2010 Sep; 8(6):461-6. PubMed ID: 20636276
[TBL] [Abstract][Full Text] [Related]
12. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.
James EA; LaFond RE; Gates TJ; Mai DT; Malhotra U; Kwok WW
J Virol; 2013 Dec; 87(23):12794-804. PubMed ID: 24049183
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.
Veit O; Niedrig M; Chapuis-Taillard C; Cavassini M; Mossdorf E; Schmid P; Bae HG; Litzba N; Staub T; Hatz C; Furrer H;
Clin Infect Dis; 2009 Mar; 48(5):659-66. PubMed ID: 19191654
[TBL] [Abstract][Full Text] [Related]
14. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG
J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231
[TBL] [Abstract][Full Text] [Related]
15. Yellow fever vaccine for patients with HIV infection.
Barte H; Horvath TH; Rutherford GW
Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
[TBL] [Abstract][Full Text] [Related]
16. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
[TBL] [Abstract][Full Text] [Related]
17. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
[TBL] [Abstract][Full Text] [Related]
19. Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.
Slifka MK; Leung DY; Hammarlund E; Raué HP; Simpson EL; Tofte S; Baig-Lewis S; David G; Lynn H; Woolson R; Hata T; Milgrom H; Hanifin J
J Allergy Clin Immunol; 2014 Feb; 133(2):439-47. PubMed ID: 24331381
[TBL] [Abstract][Full Text] [Related]
20. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
